Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction.

[1]  A. Tonkin,et al.  A Randomized Comparison of Intravenous Heparin With Oral Aspirin and Dipyridamole 24 Hours After Recombinant Tissue‐Type Plasminogen Activator for Acute Myocardial Infarction , 1991, Circulation.

[2]  R. C. Reeves,et al.  Heparin and infarct coronary artery patency after streptokinase in acute myocardial infarction. , 1990, The American journal of cardiology.

[3]  J. Hsia,et al.  Heparin versus aspirin after recombinant tissue plasminogen activator therapy in myocardial infarction: A randomized trial , 1990 .

[4]  E. Topol,et al.  A randomized pilot trial of brief versus prolonged heparin after successful reperfusion in acute myocardial infarction. , 1990, The American journal of cardiology.

[5]  V. Fuster,et al.  Antithrombotic therapy in cardiac disease. An emerging approach based on pathogenesis and risk. , 1989, Circulation.

[6]  R. Califf,et al.  Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group. , 1989, Circulation.

[7]  C. Grines,et al.  A new thrombolytic regimen for acute myocardial infarction using combination half dose tissue-type plasminogen activator with full dose streptokinase: a pilot study. KAMIT Study Group. , 1989, Journal of the American College of Cardiology.

[8]  M. Cohen,et al.  Late thrombolytic therapy preserves left ventricular function in patients with collateralized total coronary occlusion: primary end point findings of the Second Mount Sinai-New York University Reperfusion Trial. , 1989, Journal of the American College of Cardiology.

[9]  R. Califf.  Myocardial reperfusion: is it ever too late? , 1989, Journal of the American College of Cardiology.

[10]  J. Cassagnes,et al.  Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: effects on infarct size and left ventricular function. , 1989, Journal of the American College of Cardiology.

[11]  K. Lee,et al.  A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. , 1989, Circulation.

[12]  L. Tavazzi,et al.  Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction , 1989 .

[13]  F. Van de Werf,et al.  Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. , 1988, BMJ.

[14]  A. M. Skene,et al.  TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.

[15]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.

[16]  Dwight E. Peake,et al.  Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase , 1988 .

[17]  J. Anderson,et al.  Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase. , 1988, Journal of the American College of Cardiology.

[18]  R. Califf,et al.  Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. , 1988, Circulation.

[19]  A. Jaffe,et al.  Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase , 1988 .

[20]  E. B. Carlson,et al.  Coronary perfusion during acute myocardial infarction with a combined therapy of coronary angioplasty and high-dose intravenous streptokinase. , 1988, Circulation.

[21]  K. Lee,et al.  A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. , 1987, The New England journal of medicine.

[22]  R. W. Brower,et al.  Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate. , 1987, The American journal of cardiology.

[23]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[24]  Isis Pilot Study Investigation.  Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction , 1987 .

[25]  M. Winniford,et al.  Review: thrombolytic therapy for patients with acute myocardial infarction , 1987 .

[26]  M. Parker,et al.  Role of heparin after intravenous thrombolytic therapy for acute myocardial infarction. , 1987, The American journal of cardiology.

[27]  Harold T. Dodge,et al.  Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .

[28]  V. Fuster,et al.  Antithrombotic therapy for acute myocardial infarction: mechanisms and prevention of deep venous, left ventricular, and coronary artery thromboembolism. , 1986, Circulation.

[29]  G. Timmis,et al.  Hemorrhage vs rethrombosis after thrombolysis for acute myocardial infarction. , 1986, Archives of internal medicine.

[30]  I. Palacios,et al.  Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. , 1986, Circulation.

[31]  J. Spann,et al.  Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction. , 1986, The American journal of cardiology.

[32]  K. Karsch,et al.  Effects of intracoronary streptokinase and intracoronary nitroglycerin infusion on coronary angiographic patterns and mortality in patients with acute myocardial infarction. , 1984, The New England journal of medicine.

[33]  A A Tsiatis,et al.  Exact significance testing to establish treatment equivalence with ordered categorical data. , 1984, Biometrics.

[34]  S. M. Collins,et al.  Rethrombosis after reperfusion with streptokinase: importance of geometry of residual lesions. , 1984, Circulation.

[35]  M S Golden,et al.  Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. , 1980, The New England journal of medicine.

[36]  T C Chalmers,et al.  Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. , 1977, The New England journal of medicine.

[37]  T. Waterston.  Fluids for diarrhoea in young children. , 1977, Lancet.

[38]  E. Veys,et al.  Letter: HL-A and infective sacroileitis. , 1974, Lancet.

[39]  S. Gilder.  Home or Away. , 1964, Canadian Medical Association journal.

[40]  K. Lindahl-Kiessling,et al.  USE AND ABUSE OF ELECTROENCEPHALOGRAPHY. , 1964, Lancet.